isocitric acid has been researched along with Acute Myelogenous Leukemia in 2 studies
isocitric acid: RN given refers to unlabeled parent cpd
isocitric acid : A tricarboxylic acid that is propan-1-ol with a hydrogen at each of the 3 carbon positions replaced by a carboxy group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Martelli, MP | 1 |
| Martino, G | 1 |
| Cardinali, V | 1 |
| Falini, B | 1 |
| Martinelli, G | 1 |
| Cerchione, C | 1 |
| Ward, PS | 1 |
| Patel, J | 1 |
| Wise, DR | 1 |
| Abdel-Wahab, O | 1 |
| Bennett, BD | 1 |
| Coller, HA | 1 |
| Cross, JR | 1 |
| Fantin, VR | 1 |
| Hedvat, CV | 1 |
| Perl, AE | 1 |
| Rabinowitz, JD | 1 |
| Carroll, M | 1 |
| Su, SM | 1 |
| Sharp, KA | 1 |
| Levine, RL | 1 |
| Thompson, CB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevalence, Correlation With Other Mutant Genes and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia. The European IDH Research Alliance[NCT04369287] | 654 participants (Anticipated) | Observational | 2016-01-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for isocitric acid and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Enasidenib and ivosidenib in AML.
Topics: Aminopyridines; Antineoplastic Agents; Cell Differentiation; Clinical Trials as Topic; Glutarates; G | 2020 |
1 other study available for isocitric acid and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Topics: Cell Proliferation; Glutarates; Humans; Isocitrate Dehydrogenase; Isocitrates; Ketoglutaric Acids; L | 2010 |